EP4452939A4 - SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS - Google Patents

SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS

Info

Publication number
EP4452939A4
EP4452939A4 EP22912515.8A EP22912515A EP4452939A4 EP 4452939 A4 EP4452939 A4 EP 4452939A4 EP 22912515 A EP22912515 A EP 22912515A EP 4452939 A4 EP4452939 A4 EP 4452939A4
Authority
EP
European Patent Office
Prior art keywords
antagonists
polypodal
prodrugs
serotonin receptor
serotonergic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22912515.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4452939A1 (en
Inventor
David Gilles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuleon LLC
Original Assignee
Kuleon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuleon LLC filed Critical Kuleon LLC
Publication of EP4452939A1 publication Critical patent/EP4452939A1/en
Publication of EP4452939A4 publication Critical patent/EP4452939A4/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22912515.8A 2021-12-24 2022-12-23 SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS Pending EP4452939A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163293730P 2021-12-24 2021-12-24
US202263299817P 2022-01-14 2022-01-14
US202263338994P 2022-05-06 2022-05-06
PCT/US2022/053910 WO2023122320A1 (en) 2021-12-24 2022-12-23 Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists

Publications (2)

Publication Number Publication Date
EP4452939A1 EP4452939A1 (en) 2024-10-30
EP4452939A4 true EP4452939A4 (en) 2025-12-10

Family

ID=86903690

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22912515.8A Pending EP4452939A4 (en) 2021-12-24 2022-12-23 SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS

Country Status (3)

Country Link
EP (1) EP4452939A4 (https=)
JP (1) JP2025500321A (https=)
WO (1) WO2023122320A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023319280A1 (en) * 2022-08-05 2025-03-20 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024081961A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Ester analogs of psilocin, processes for the preparation thereof, and methods of use
WO2025045773A1 (en) * 2023-08-25 2025-03-06 Compass Pathfinder Limited 3-(2-(dimethylamino)ethyl)-1h-indol-4-yl oligomeric derivatives
WO2025122513A1 (en) * 2023-12-04 2025-06-12 Delix Therapeutics, Inc. Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines
US20260021070A1 (en) * 2024-07-19 2026-01-22 Compass Pathfinder Limited Subcutaneous formulations comprising psilocybin derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026923A1 (fr) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
WO2023173227A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
WO2024026574A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024026573A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024081961A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Ester analogs of psilocin, processes for the preparation thereof, and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521683A (ja) * 2013-05-24 2016-07-25 ネステク ソシエテ アノニム 過敏性腸症候群の診断を予測するための経路特異的なアッセイ
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
CA3188636A1 (en) * 2020-08-21 2022-02-24 Matthias GRILL Novel psilocin derivatives having prodrug properties

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026923A1 (fr) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Nouveaux derives bi-tryptaminiques, leur procede de preparation et leur utilisation a titre de medicaments
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
WO2023173227A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
WO2024026574A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024026573A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
WO2024081961A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Ester analogs of psilocin, processes for the preparation thereof, and methods of use

Also Published As

Publication number Publication date
EP4452939A1 (en) 2024-10-30
JP2025500321A (ja) 2025-01-09
WO2023122320A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
EP4452939A4 (en) SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
PE20180686A1 (es) Compuestos nuevos como moduladores de ror gamma
EP3478283A4 (en) USE OF NEUROKININ-1 ANTAGONISTS IN THE TREATMENT OF A VARIETY OF PRURITIUS CONDITIONS
EP4143305A4 (en) GENETICALLY MODIFIED CENTRAL NERVOUS SYSTEM COMPOSITIONS
EA201891615A1 (ru) Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора
PE20190913A1 (es) Derivados aromaticos de sulfonamida
DK3407889T3 (da) Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
MX391031B (es) Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
EP3912975A4 (en) Lysophosphatidic acid receptor antagonists and preparation method therefor
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
EA201691167A1 (ru) Аналоги кортистатина, их синтез и применения
AR059905A1 (es) Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto
EA201000946A1 (ru) Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20170129A1 (es) Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t
MX2017009625A (es) Compuestos macrociclicos como inhibidores de cinasas asociadas al receptor de interleucina1/4 (irak1/4) y usos de los mismos.
DOP2011000326A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)- bencensulfonamida o bencensulfonil-fenil-(pipezina u homopiperazina) adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
PA8845601A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1(trpv1)
CO6511237A2 (es) Dihidrobenzocicloalquiloximetl-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
AR063147A1 (es) Compuestos heterociclicos nitrogenados inhibidores de receptores de histamina h3, metodo de preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de trastornos del sistema nervioso central.
EP3525779C0 (de) Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone
EA201691413A1 (ru) Селективные антагонисты nr2b
EP4208446A4 (en) PSILOCYBIN NITROGEN DERIVATIVES AND ASSOCIATED USE FOR THE MODULATION OF THE 5-HT2A RECEPTOR AND FOR THE TREATMENT OF A PSYCHIATRIC DISORDER
EA201890695A1 (ru) Новые пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 209/16 20060101AFI20251104BHEP

Ipc: C07D 401/14 20060101ALI20251104BHEP

Ipc: C07D 401/12 20060101ALI20251104BHEP

Ipc: C07D 413/12 20060101ALI20251104BHEP

Ipc: C07D 403/06 20060101ALI20251104BHEP

Ipc: A61K 31/4045 20060101ALI20251104BHEP

Ipc: A61P 25/22 20060101ALI20251104BHEP